Press Room

Webinar - Heavy Metals determination by UPLC

Start
Thursday, January 29, 2015 - 14:00
End
Thursday, January 29, 2015 - 15:00

Speakers

António Ramos

Analytical Development Group Leader 

Lúcia Volta e Sousa

PhD Student / Analytical Chemist

 

Elemental impurities analysis has a great importance within pharmaceutical realm due to its impact on the quality, safety and efficacy of drug product and substances. These impurities can include catalysts and environmental contaminants that may be present in drug substances, excipients or drug product. For that reason, it is necessary to have a rigid control, during the manufacturing process in order to assure that the final product is within the specification limits described in the USP chapter 232> and recently approved ICH Q3D guideline. There are two procedures acknowledge by USP that can be used to analyze and control these materials, as ICP-MS and ICP-AES. These techniques are expensive and most of the times are not available in every manufacturing sites. According to USP 233> acceptable alternative procedures that meet validation requirements can be used. An alternative Microwave / UPLC / UV-VIS provides a powerful, advantageous and fast solution for heavy metals determination with improvements in terms of time and costs. The breakthrough is the use of microwave based digestion to obtain a universal method that can be applied to any organic matrix. The use of a Quality by Design approach will allow for a better understanding of the method design space and a more effective method development.

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026